

---

**Galley Proof IJP 30 No 1 2019**

2 messages

---

**Majalah Farmasi** <mfi@ugm.ac.id>  
To: budi-s@ff.unair.ac.id

Fri, Mar 29, 2019 at 1:17 PM

Dear Budi Suprapti, et al.

Your manuscript has been accepted for publication in Indonesian Journal of Pharmacy (attached 1). On behalf of Editorial team, we are looking forward to receiving your new paper. Please sign the copyright transfer (attached 2) in order to allow me to process your manuscript. Please check the proof (attached 3) carefully and if you need revision you can write in file (attached 4).

Your revised manuscript and Copyright Form must be returned to us within 4 days (April 1, 2019). Please refer to the attached documents below.

Sincerely,

Editorial Staff

---

**4 attachments**

-  **2. Copyright from - MFI.docx**  
67K
-  **1. LOA Budi Suprapti.pdf**  
277K
-  **3. Budi Suprapti Galley Proof.pdf**  
434K
-  **4. Budi Suprapti.docx**  
149K

---

**budi suprapti** <budi-s@ff.unair.ac.id>  
To: Majalah Farmasi <mfi@ugm.ac.id>

Mon, Apr 1, 2019 at 11:46 PM

Dear Editorial of IJP

Related to my paper I attached:

1. Revised Budi Suprapti docx file, where i have make some correction or omitted some word as shown in yellow colour in file Budi Suprapti Galey Proof
2. Copyright form

Thank You for allowing us to contribute publish our paper in IJP.




Regards

Budi Suprapti

[Quoted text hidden]

---

**3 attachments**

-  **4. REVISED Budi Suprapti.docx**  
168K
-  **3. Budi Suprapti Galley Proof.pdf**  
564K
-  **Budi Suprapti Copy right form.pdf**  
658K

**KWITANSI PEMBAYARAN  
MAJALAH FARMASI INDONESIA**

---

Telah terima dari:

Nama : Dr. Budi Suprapti  
Alamat : Fakultas Farmasi Universitas Airlangga  
Uang sebesar : 1.500.000

Terbilang : *Satu juta lima ratus ribu rupiah*

Guna Membayar Majalah:

*Biaya Pembayaran Publikasi di Indonesian Journal of Pharmacy, Vol 30 No 1 2019.*

Yogyakarta, 29 Agustus 2019

Penerima,



Puma Arfah

## Re: [IJP] Editor Decision

---

Dari: Majalah Farmasi (mfi@ugm.ac.id)

Kepada: budiprapti@yahoo.co.id

Tanggal: Senin, 25 Maret 2019 14.40 WIB

---

Berikut kami kirimkan invois nya.

trimkasih

On Mon, Mar 25, 2019 at 2:10 PM Editorial MFI <[mfi@ugm.ac.id](mailto:mfi@ugm.ac.id)> wrote:

Dear Dr. Budi Suprpti

We have reached a decision regarding your submission to Indonesian Journal of Pharmacy, "Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1".

We are pleased to confirm that your manuscript entitled Indonesian Journal of Pharmacy, "Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1". has been accepted for publication in Indonesian journal of Pharmacy. However, please make payment to BNI (Account holder: Mawardi Ihsan, Account No. 0140244118), SWIFT: BNINIDJAXXX before we could send you the official letter of acceptance.

Thank you very much for submitting your manuscript to the Indonesian Journal of Pharmacy

Regards  
Editor in Chief,  
Indonesian Journal of Pharmacy

Prof. Dr. Sugiyanto

---

INDONESIAN JOURNAL OF PHARMACY  
Faculty of Pharmacy, Universitas Gadjah Mada  
Skip Utara, 55281 Yogyakarta



INVOIS Budi S.pdf  
396.6kB

## [IJP] Editor Decision

---

Dari: Editorial MFI (mfi@ugm.ac.id)

Kepada: budiprapti@yahoo.co.id

Tanggal: Jumat, 8 Maret 2019 15.10 WIB

---

Dear Budi Suprapti

We have reached a decision regarding your submission to Indonesian Journal of Pharmacy, "Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1". Your manuscript has been reviewed, by our reviewer, Please add some reviewer suggestion below

Introduction:

Describe the relationship between paricalcitol and TRAP5b, b-ALP and DKK1

Methodology:

1. Describe design of the study
2. Provide inclusion and exclusion criteria for research subject.

Result and Discussion:

1. Discuss the figure presented (figure 1-6)
2. Integrate the result presented in that figure in case discussion.
3. Discuss the limitation of the study (varying baseline, therapeutic regimen, some confounding factor)
4. Provide general discussion of all cases

If you could revise your manuscript during 4 day, your manuscript will be consider to publish on this issue.

---

INDONESIAN JOURNAL OF PHARMACY  
Faculty of Pharmacy, Universitas Gadjah Mada  
Skip Utara, 55281 Yogyakarta